DaVita Q2 FY26 operating income climbs 20.1% to $579 million; revenue rises 4% to $3.55 billion

• DaVita Q2 2026 operating income rose 20.1% to $579 million as revenue climbed 4% to $3.55 billion.
• Six-month net income increased 21.9% to $618 million as operating income rose 8.6% to $1.06 billion.
• U.S. dialysis Q2 revenue rose 2.4% to $3.01 billion while treatments increased 2.8% to 7,226,600.
• U.S. dialysis patient service revenue per treatment slipped 0.4% to $415.87; patient care costs per treatment fell 1% to $277.40.
• Integrated kidney care swung to Q2 operating income of $40 million on higher shared savings; plans to roll out expanded HD broadly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DaVita Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000927066-26-000108), on August 04, 2026, and is solely responsible for the information contained therein.